CRANEWARE PLC

Declaration of Voting Results & Voting Rights Announcements • Nov 22, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3832U

Craneware plc

22 November 2019

Craneware plc

("Craneware" or the "Company")

Total Voting Rights

In accordance with the Disclosure and Transparency Rules, Craneware announces that at the date of this notice its issued share capital comprises 26,816,207 ordinary shares of 1p ("Ordinary Shares") each with voting rights.

No Ordinary Shares are held in treasury.

The total voting rights in the Company is therefore 26,816,207. The voting rights of all of the Ordinary Shares are identical.

The figure above may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Craneware, under the Disclosure and Transparency Rules.

For further information, please contact:

Craneware plc	Peel Hunt (NOMAD & Joint Broker)	Investec Bank (Joint Broker)	Alma (Financial PR)
+44 (0)131 550 3100	+44 (0)20 7418 8900	+44 (0)20 7597 5970	+44 (0)203 405 0205
Keith Neilson, CEO	Dan Webster	Patrick Robb	Caroline Forde
Craig Preston, CFO	George Sellar	Sebastian Lawrence	Hilary Buchanan
	Guy Pengelley	Henry Reast	Helena Bogle

About Craneware

Craneware enables healthcare providers to improve margins and enhance patient outcomes so they can continue to provide quality outcomes for all.

Craneware is the leader in automated Value Cycle solutions that help US Healthcare provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware is headquartered in Edinburgh, Scotland with offices in Atlanta and Pittsburgh employing over 350 staff. Craneware's market-driven, SaaS solutions normalise disparate data sets, bringing in up-to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit craneware.com and thevaluecycle.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRCKBDPKBDDCDB